loading
Schlusskurs vom Vortag:
$3.98
Offen:
$4.02
24-Stunden-Volumen:
292.71K
Relative Volume:
1.06
Marktkapitalisierung:
$130.88M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.7252
EPS:
-1.11
Netto-Cashflow:
$-31.03M
1W Leistung:
-3.26%
1M Leistung:
-28.77%
6M Leistung:
-66.10%
1J Leistung:
+356.99%
1-Tages-Spanne:
Value
$3.965
$4.2999
1-Wochen-Bereich:
Value
$3.785
$4.43
52-Wochen-Spanne:
Value
$0.77
$14.30

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Firmenname
Candel Therapeutics Inc
Name
Telefon
617-916-5445
Name
Adresse
117 KENDRICK STREET, NEEDHAM
Name
Mitarbeiter
42
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CADL's Discussions on Twitter

Vergleichen Sie CADL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CADL 4.14 130.88M 124.00K -49.99M -31.03M -1.11
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.00 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.61 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.08 24.89B 3.30B -501.07M 1.03B 11.54

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-12-02 Eingeleitet H.C. Wainwright Buy
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-08-23 Eingeleitet Credit Suisse Outperform
2021-08-23 Eingeleitet Jefferies Buy
2021-08-23 Eingeleitet UBS Buy

Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten

pulisher
Nov 20, 2024

FY2024 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Analysts Issue Forecasts for CADL Q4 Earnings - Defense World

Nov 20, 2024
pulisher
Nov 20, 2024

HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

What is HC Wainwright's Forecast for CADL Q4 Earnings? - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Reaffirms "Buy" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Candel Therapeutics Inc (CADL) Quarterly 10-Q Report - Quartz

Nov 15, 2024
pulisher
Nov 14, 2024

Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up - Proactive financial news

Nov 14, 2024
pulisher
Nov 14, 2024

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Candel Therapeutics Reports $10.6M Q3 Loss, Advances Key Cancer Drug Trials for Q4 2024 | CADL Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 12, 2024

Insiders Could Have Profited By Holding onto Candel Therapeutics Shares Despite 10% Drop - Simply Wall St

Nov 12, 2024
pulisher
Nov 09, 2024

Candel Therapeutics’ CAN-3110 offers new hope for melanoma treatment – ICYMI - Proactive Investors USA

Nov 09, 2024
pulisher
Nov 07, 2024

CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Candel Therapeutics CEO to present at Jefferies London healthcare conference - Proactive Investors UK

Nov 07, 2024
pulisher
Nov 07, 2024

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Candel Therapeutics (NASDAQ:CADL) Shares Up 2.5%Should You Buy? - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual Meeting - Proactive Investors USA

Nov 06, 2024
pulisher
Nov 06, 2024

Candel Therapeutics to Present Preclinical Data at SITC - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results - Proactive Investors UK

Nov 05, 2024
pulisher
Nov 05, 2024

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Nfi Group Inc. (NFI-T) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Nov 01, 2024

Candel Therapeutics: A Low-Price Oncolytic Virus Play Further Along Than You Think - Seeking Alpha

Nov 01, 2024
pulisher
Oct 29, 2024

Candel Therapeutics Advances in Cancer Treatment Trials - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Candel Therapeutics Showcases Innovative Cancer Therapy - GlobeNewswire

Oct 29, 2024
pulisher
Oct 28, 2024

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) - StockTitan

Oct 28, 2024
pulisher
Oct 26, 2024

Candel Therapeutics Prices IPO At $8/Share - RTTNews

Oct 26, 2024
pulisher
Oct 26, 2024

Where are the Opportunities in (CADL) - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 18, 2024

Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End - Proactive Investors Australia

Oct 18, 2024
pulisher
Oct 17, 2024

Candel Therapeutics Share PriceCADL, RNS News, Articles, Quotes, & Charts (NASDAQ:CADL) - Proactive Investors USA

Oct 17, 2024
pulisher
Oct 15, 2024

(CADL) Trading Advice - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 10, 2024

Banxa Holdings Inc (BNXAF) QuotePress Release - The Globe and Mail

Oct 10, 2024
pulisher
Oct 05, 2024

How To Trade (CADL) - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 04, 2024

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - The Manila Times

Oct 04, 2024
pulisher
Oct 04, 2024

Candel Therapeutics to Present Preclinical Data on - GlobeNewswire

Oct 04, 2024
pulisher
Oct 04, 2024

Candel therapeutics insider sells shares worth over $240k By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

Candel therapeutics insider sells shares worth over $240k - Investing.com India

Oct 04, 2024
pulisher
Oct 03, 2024

Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares - MarketBeat

Oct 03, 2024
pulisher
Sep 24, 2024

Citigroup Raises Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Citi raises Cogent price target on bezuclastinib potential - Investing.com India

Sep 24, 2024
pulisher
Sep 24, 2024

Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

(CADL) Proactive Strategies - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Gaining Ground: Cogent Biosciences Inc (COGT) Closes Lower at 10.65, Down -3.01 - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

Cintas Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

Farallon Capital Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Kayne Anderson Rudnick Investment Management LLC Trims Holdings in Copart, Inc. (NASDAQ:CPRT) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Circassia Pharmaceuticals Announces Strong H1 2024 Results - TipRanks

Sep 24, 2024

Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):